Trade name
Adrenaline (Aspen), Adrenaline Juno, Adrenaline Jr Viatris, Adrenaline Viatris, Adrenaline-Link, Anapen, EpiPen, EpiPen Jr
Adrenaline (Aspen), Adrenaline Juno and Adrenaline-Link contain adrenaline acid tartrate.
Strength
Ampoule and prefilled syringe:
0.1 mg/mL [1:10 000] (volume: 10 mL)
Ampoule:
1 mg/mL [1:1000] (volume: 1 mL)
Auto-injector (Adrenaline Jr Viatris, Adrenaline Viatris, Anapen 500, EpiPen, EpiPen Jr):
0.15 mg/0.3 mL
0.3 mg/0.3 mL
0.5 mg/0.3 mL
IV administration
IV route: Administer under specialist supervision in appropriate healthcare settings.
Ampoule and prefilled syringe only:
IV injection: use 0.1 mg/mL (1:10 000) strength and give by slow IV injection.
In resuscitation, may be given by rapid IV injection.
If given peripherally, follow with a sodium chloride 0.9% flush.
IV continuous infusion: Follow local protocol or use 1 mg/mL (1:1000) strength and give as a continuous infusion, preferably via a central line.
Infuse via a dedicated IV line, using a syringe or infusion pump with DERS.
Other routes of administration
IM: Suitable and preferred route for anaphylaxis.
Ampoule and prefilled syringe: Use 1 mg/mL (1:1000) strength and inject into the outer-mid thigh. Do not inject into the buttocks.
Auto-injector: Brand-specific administration instructions; refer to Product Information and ASCIA guidelines for detailed information.
SC: Not recommended, due to delayed and erratic absorption.
Compatible IV fluids
Adrenaline (epinephrine) hydrochloride:
Glucose 5%
Glucose 5% and sodium chloride 0.9%
Glucose 5% and sodium chloride 0.45%
Glucose 10%
Hartmann’s
Sodium chloride 0.9%
Y-site only:
Potassium chloride 20 mmol/L
Y-site only and adrenaline (epinephrine) 0.25 mg/mL or weaker:
Plasma-Lyte 148
Adrenaline (epinephrine) acid tartrate is commonly diluted with the listed IV fluids in practice, despite minimal compatibility and stability data.
Additional information
Extravasation risk.
Check strength of selected product carefully.
IV route: Use only when facilities for cardiac monitoring and cardio-respiratory resuscitation exist.
Taper the IV infusion slowly when discontinuing treatment.
Repeated IM or SC injections to the same site may cause ischaemia and necrosis.
Periodically check Auto-Injectors to ensure solution is not discoloured.
Protect from light during storage.